-
公开(公告)号:US20050287136A1
公开(公告)日:2005-12-29
申请号:US11128900
申请日:2005-05-12
申请人: Douglas Hanson , Mark Neveu , Eileen Mueller , Jeffrey Hanke , Steven Gilman , C. Davis , Jose Corvalan
发明人: Douglas Hanson , Mark Neveu , Eileen Mueller , Jeffrey Hanke , Steven Gilman , C. Davis , Jose Corvalan
IPC分类号: A61K39/395 , C07K16/28 , G01N33/53 , G01N33/567 , G01N33/569 , G01N33/68
CPC分类号: C07K16/2818 , A61K39/39558 , A61K2039/505 , C07K2317/21 , C07K2317/24 , G01N33/56972 , G01N33/6863
摘要: In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.
摘要翻译: 根据本发明,提供了针对人细胞毒性T淋巴细胞抗原4(CTLA-4)的完全人单克隆抗体。 提供了编码尼罗肽的序列和包含重链和轻链免疫球蛋白分子,特别是跨越互补决定区(CDR)的连续重链和轻链序列,特别是来自FR1和/或CDR1至CDR3和/或FR4内的重链和轻链序列。 还提供了具有相似结合特性的抗体和具有与本文公开的抗体相似功能的抗体(或其它拮抗剂)。
-
公开(公告)号:US20050226875A1
公开(公告)日:2005-10-13
申请号:US11085368
申请日:2005-03-21
IPC分类号: A61K9/00 , A61K39/395 , A61K45/00 , A61K47/26 , C07K16/28
CPC分类号: C07K16/2818 , A61K9/0019 , A61K47/26 , A61K2039/505 , C07K2317/21 , C07K2317/73
摘要: The invention relates to treatment of cancer in a mammal who has undergone stem cell transplantation by administering an effective amount of a human anti-CTLA-4 antibody to the mammal. Stem cell transplantation may be allogeneic or autologous stem cell transplantation and may be preceded by a preparatory treatment such as chemotherapy. The methods of the invention may be combined with additional cancer treatments. Further, the invention relates to treatment of cancer using at least 10 mg/kg of a human anti-CTLA-4 antibody, and, more preferably, about 15-20 mg/kg of antibody.
摘要翻译: 本发明涉及通过向哺乳动物施用有效量的人抗CTLA-4抗体,已经经历了干细胞移植的哺乳动物的癌症治疗。 干细胞移植可以是同种异体或自体干细胞移植,并且之前可以进行诸如化疗的预备治疗。 本发明的方法可以与另外的癌症治疗组合。 此外,本发明涉及使用至少10mg / kg人抗CTLA-4抗体,更优选约15-20mg / kg抗体治疗癌症。
-